Wedbush Securities’s Provention Bio, Inc. Common Stock PRVB Stock Holding History

Wedbush Securities’s Portfolio PRVB Stock Details PRVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-11,000	Closed	-$265K	–	1139
2023 Q1	$265K	Sell	11,000 -2,000	-15%	-$25.1K	0.01%	806
2022 Q4	$137K	Hold	13,000	–	–	0.01%	960
2022 Q3	$59K	Hold	13,000	–	–	﹤0.01%	1003
2022 Q2	$52K	Hold	13,000	–	–	﹤0.01%	1031
2022 Q1	$95K	Hold	13,000	–	–	﹤0.01%	1060
2021 Q4	$73K	Buy	13,000 +2,000	+18%	+$12.7K	﹤0.01%	1145
2021 Q3	$70K	Hold	11,000	–	–	﹤0.01%	1147
2021 Q2	$93K	Hold	11,000	–	–	﹤0.01%	1134
2021 Q1	$115K	Buy	+11,000	New	+$155K	0.01%	1038

Other funds holding PRVB

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Wedbush Securities's PRVB Position: Q2 2023 in Review

Wedbush Securities sold out of Provention Bio, Inc. Common Stock (PRVB) in Q2 2023, closing a stake of 11,000 shares — an estimated $265K sold.

Wedbush Securities first reported a position in PRVB in Q1 2021 and held it in 9 quarters. The position peaked at $265K in Q1 2023. 1 fund tracked by Wall St. Rank holds PRVB as of Q2 2023.

Wedbush Securities reported no remaining Provention Bio, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Wedbush Securities sold 11,000 Provention Bio, Inc. Common Stock shares in Q2 2023, an estimated $265K.
Wedbush Securities first reported a position in Provention Bio, Inc. Common Stock in Q1 2021 and held it in 9 quarters.
Wedbush Securities's Provention Bio, Inc. Common Stock position peaked at $265K in Q1 2023.
1 fund tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q2 2023.

Based on Wedbush Securities's 13F filing for Q2 2023, filed 14 Aug 2023.